Skip to search formSkip to main contentSkip to account menu

TG02

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02
Standards of care for meningioma include surgical resection and radiotherapy whereas pharmacotherapy plays almost no role in this… 
2019
2019
Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults.
2031 Background: Therapies targeting multiple survival pathways simultaneously may be more effective for high-grade gliomas, a… 
2018
2018
Centimeter-Level Orbit Determination for TG02 Spacelab Using Onboard GNSS Data
Tiangong-2, the second Chinese manned spacecraft, was launched into low Earth orbit on 15 September 2016. The dual-frequency… 
2017
2017
EXTH-67. TG02, A BRAIN-PENETRANT MULTI-CDK INHIBITOR, POTENTLY SUPPRESSES MYC-DRIVEN GLIOBLASTOMA
2017
2017
Abstract 1533: Transcriptional inhibition of brachyury in chordoma is associated with adoption of quiescent phenotype
BACKGROUND: Brachyury is a mesoderm specification transcription factor involved in notochord development and overexpressed in a… 
2014
2014
Abstract 4536: ABT-737 and ABT-199 complement the multikinase inhibitor TG02 to induce apoptosis in acute myeloid leukemia cells
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA TG02 is a novel multikinase inhibitor currently in Phase 1… 
2013
2013
Cancer Therapy : Preclinical Potent Antimyeloma Activity of a Novel ERK 5 / CDK Inhibitor
Purpose: To analyze the antimyeloma potential of TG02, an ERK5/CDK inhibitory drug. Experimental Design: Utilizing different… 
2012
2012
Abstract 2830: Multikinase inhibition by TG02 is therapeutically effective in two forms of breast cancer
Breast cancer (BC) is a heterogeneous disease in which several distinct genetic and histopathological types have been defined… 
2010
2010
Antimyeloma Action of the Multikinase Inhibitor TG02
Abstract 4062 Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable, despite recent… 
2010
2010
83 Effect of TG02, a kinase inhibitor targeting Erk5, on triple negative breast cancer cells
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)